Friday, August 18, 2017
Company Reports Revenue of $5.3 Million for Q2 2017-  Continued Progress on Building a Consumer Products Platform Around TruNiagen®- IRVINE, Calif., Aug. 10, 2017 (GLOBE NEWSWIRE) -- ChromaDex Corp. (CDXC), an innovator of proprietary health, wellness and nutritional ingredients,...
IRVINE, Calif., June 27, 2017 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC), an innovator of proprietary health, wellness and nutritional ingredients that creates science-based solutions for dietary supplement, food and beverage, skin care, sports nutrition, and pharmaceutical products announced today that it has appointed...
This morning we have added Chromadex to the Tailwinds Select Portfolio at a price of $3.91. Chromadex holds the worldwide rights to Niagen, a member of the vitamin B-3 family that helps promote healthier living and longer lives. CDXC...
IRVINE, Calif., June 12, 2017 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC), an innovator of proprietary health, wellness and nutritional ingredients that creates science-based solutions for dietary supplement, food and beverage, skin care, sports nutrition, and pharmaceutical products announced today that it has signed...
IRVINE, Calif., June 05, 2017 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC), an innovator of proprietary health, wellness and nutritional ingredients that creates science-based solutions for dietary supplement, food and beverage, skin care, sports nutrition, and pharmaceutical products announced today that Charles Brenner, PhD, the...
Follow

Follow this blog

Get every new post delivered right to your inbox.

Email address